Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Sleep disorders constitute major nonmotor features of Parkinson’s disease (PD) that have a substantial effect on patients’ quality of life and can be related to the progression of the neurodegenerative disease. They can also serve as preclinical markers for PD, as it is the case for rapid eye movement (REM)-associated sleep behavior disorder (RBD). Although the etiology of sleep disorders in PD remains undefined, the assessment of the components of the circadian system, including melatonin secretion, could give therapeutically valuable insight on their pathophysiopathology. Melatonin is a regulator of the sleep/wake cycle and also acts as an effective antioxidant and mitochondrial function protector. A reduction in the expression of melatonin MT 1 and MT 2 receptors has been documented in the substantia nigra of PD patients. The efficacy of melatonin for preventing neuronal cell death and for ameliorating PD symptoms has been demonstrated in animal models of PD employing neurotoxins. A small number of controlled trials indicate that melatonin is useful in treating disturbed sleep in PD, in particular RBD. Whether melatonin and the recently developed melatonergic agents (ramelteon, tasimelteon, agomelatine) have therapeutic potential in PD is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phototransduction by retinal ganglion cells that set the circadian clock
Berson, D. M., Dunn, F. A., & Takao, M. (2002) · Science · doi:10.1126/science.1067262 · Cited by 3,629 · cited 1×
“Special photoreceptive retinal ganglion cells containing melanopsin as a photopigment are involved in the projection from retina [Berson et al. 2002; Brainard et al. 2001].”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“In addition, a dysfunctional blood brain barrier also appears to be involved in the progression of the disease [Monahan et al. 2008; Zlokovic, 2008; Kortekaas et al. 2005].”
BackgroundNon-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 2×
“Neuropsychiatric symptoms, such as vivid dreams, nightmares and nocturnal hallucinations, or RBD, are commonly observed in PD [Chaudhuri et al. 2006, 2002; Dhawan et al. 2006a, 2006b; Grandas and Iranzo, 2004].”
BackgroundDibner, C., Schibler, U., & Albrecht, U. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135821 · Cited by 2,421
Kondratov, R. V., Kondratova, A. A., Gorbacheva, V. Y., Vykhovanets, O. V., & Antoch, M. P. (2006) · Genes & Development · doi:10.1101/gad.1432206 · Cited by 1,188 · cited 1×
“Disruptions of Bmal1 and Per1 expression in mice brought about altered circadian behavior and dysregulation of circadian patterns in cell function [Kondratov et al. 2006; Cermakian et al. 2001].”
BackgroundTansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Melatonin: Nature’s most versatile biological signal?
Pandi‐Perumal, S. R., Srinivasan, V., Maestroni, G. J. M., Cardinali, D. P., Poeggeler, B., & Hardeland, R. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05322.x · Cited by 875 · cited 2×
“…occurs in various other regions of the body such as the gastrointestinal tract, skin, lymphocytes, platelets, bone marrow cells, retina, or thymus [Hardeland et al. 2011; Reiter et al. 2010; Pandi-Perumal et al. 2006b], in all of these tissues melatonin has either an autocrine or a paracrine role.”
BackgroundSelf-citationMelatonin—A pleiotropic, orchestrating regulator molecule
Hardeland, R., Cardinali, D. P., Srinivasan, V., Spence, D. W., Brown, G. M., & Pandi-Perumal, S. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.12.004 · Cited by 843
Self-citationClassic toxin-induced animal models of Parkinson?s disease: 6-OHDA and MPTP
Schober, A. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0938-y · Cited by 803
Cited by
Melatonin and inflammation-Story of a double-edged blade
Hardeland, R. (2018) · Journal of Pineal Research · doi:10.1111/jpi.12525 · Cited by 455
Self-citationSleep and Circadian Rhythm Regulation in Early Parkinson Disease
Breen, D. P., Vuono, R., Nawarathna, U., Fisher, K., Shneerson, J. M., Reddy, A. B., & Barker, R. A. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.65 · Cited by 440
Aging, melatonin, and the pro- and anti-inflammatory networks
Hardeland, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051223 · Cited by 337
Self-citationSleep Medicine - Asleep or Awake?
(2024) · doi:10.5772/intechopen.104201 · Cited by 5
Metadata
- Authors
- Srinivasan, V., Cardinali, D. P., Srinivasan, U. S., Kaur, C., Brown, G. M., Spence, D. W., Hardeland, R., & Pandi-Perumal, S. R.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2011-07-04
- Volume
- 4
- Issue
- 5
- Pages
- 297-317
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W2103958324
- Cited by
- 113
- References
- 29
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection. https://app.cochat.ai/papers/10.1177/1756285611406166
- The paper
- Srinivasan, V., Cardinali, D. P., Srinivasan, U. S., Kaur, C., Brown, G. M., Spence, D. W., Hardeland, R., & Pandi-Perumal, S. R. (2011). Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756285611406166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.